- Home
- TGTX vs HR Comparison
TGTX vs HR Comparison
Compare TGTX & HR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- HR
- Stock Information
- Founded
- TGTX 1993
- HR 1992
- Country
- TGTX United States
- HR United States
- Employees
- TGTX N/A
- HR N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- HR Real Estate Investment Trusts
- Sector
- TGTX Health Care
- HR Real Estate
- Exchange
- TGTX Nasdaq
- HR Nasdaq
- Market Cap
- TGTX 5.5B
- HR 6.4B
- IPO Year
- TGTX 1995
- HR 1993
- Fundamental
- Price
- TGTX $33.20
- HR $18.24
- Analyst Decision
- TGTX Strong Buy
- HR Hold
- Analyst Count
- TGTX 4
- HR 8
- Target Price
- TGTX $54.75
- HR $19.57
- AVG Volume (30 Days)
- TGTX 2.2M
- HR 3.1M
- Earning Date
- TGTX 11-03-2025
- HR 10-30-2025
- Dividend Yield
- TGTX N/A
- HR 5.27%
- EPS Growth
- TGTX N/A
- HR N/A
- EPS
- TGTX 2.78
- HR N/A
- Revenue
- TGTX $531,898,000.00
- HR $1,204,680,000.00
- Revenue This Year
- TGTX $82.31
- HR N/A
- Revenue Next Year
- TGTX $49.05
- HR N/A
- P/E Ratio
- TGTX $11.98
- HR N/A
- Revenue Growth
- TGTX 100.88
- HR N/A
- 52 Week Low
- TGTX $25.28
- HR $14.09
- 52 Week High
- TGTX $46.48
- HR $18.97
- Technical
- Relative Strength Index (RSI)
- TGTX 55.65
- HR 54.28
- Support Level
- TGTX $30.15
- HR $17.46
- Resistance Level
- TGTX $33.79
- HR $18.41
- Average True Range (ATR)
- TGTX 1.18
- HR 0.32
- MACD
- TGTX 0.29
- HR 0.02
- Stochastic Oscillator
- TGTX 87.33
- HR 82.01
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.